

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/616,046-Conf. #9782	
			Filing Date	July 8, 2003	
			First Named Inventor	Mladen Mercep, et al.	
			Art Unit	1615	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	03818/100L652-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			
CP	AA	US-2004/0033969-A1	02-19-2004	Burnet et al.	
CP	AB	US-2004/0005641-A1	01-08-2004	Burnet et al.	
CP	AC	US-2001/0006962-A1	07-05-2001	Myhren et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number-Kind Code ⁴ (# known)			
CP	BA	WO	97/41255	11-06-1997	Massachusetts Institute of Technology	
CP	BB	WO	00/64882	11-02-2000	Glaxo Group Ltd.	
CP	BC	WO	99/64040	12-16-1999	Advanced Medicine Inc.	
CP	BD	WO	02/055531	07-18-2002	Pliva d.d.	
CP	BE	WO	03/070254	08-28-2003	Sympore GMBH	
CP	BF	WO	03/070174-A2	08-28-2003	Sympore GMBH	
CP	BG	WO	03/070173-A2	08-28-2003	Sympore GMBH	
CP	BH	EP	0 283 055	09-21-1998	Pliva Pharm & Chem Works	
CP	BI	EP	0 895 999	02-10-1999	Pfizer Products, Inc.	
CP	BJ	GB	2 327 084	01-13-1999	Merck & Co., Inc.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
CP	CA	Burnet et al., "Conjugates of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof," U.S. Provisional Application No. 60/357,789, filed February 15, 2002.		
CP	CB	Brandt-Rauf et al., "Fluorescent Assay For Estimating the Binding of Erythromycin Derivatives to Ribosomes," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, D.C., 14(1):88-94. (1978).		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>G. P. P. P.</i>	Date Considered	8/5/04
--------------------	--------------------	-----------------	--------



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Patent Information Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/616,046
				Filing Date	July 8, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	5	Attorney Docket Number	03818/100L652-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
G	1.	6,297,260	10/02/2001	Bandarage et al.	
G	2.	4,710,495	12/01/1987	Bodor	
G	3.	6,402,733	06/11/2002	Daugherty	
G	4.	6,273,086	08/14/2001	Ohki et al.	
G	5.	6,228,346	05/08/2001	Zhang et al.	
G	6.	5,747,467	05/05/1988	Agouridas et al.	
G	7.	4,474,768	10/02/1984	Bright	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² -Number-Kind Code ³ (if known)				
G	8.	WO 94/13690 ✓	06/23/1992	Rhone-Poulenc Rorer Limited		
G	9.	WO 94/14834 ✓	07/07/1994	Rhone-Poulenc Rorer Limited		
G	10.	WO 92/13873 ✓	08/20/1992	Aktiebolaget Astra		
G	11.	WO 92/13872 ✓	08/20/1992	Aktiebolaget Astra		
G	12.	WO 00/42055 ✓	07/20/2000	Zambon Group S.P.A.		
G	13.	EP 0283055 ✓	08/29/1990	Sour Pliva farmaceutska		
G	14.	EP 0775489 ✓ -	05/28/1997	Taisho Pharmaceutical Co. Ltd.		
G	15.	EP 0771564 ✓ -	05/07/1997	Taisho Pharmaceutical Co. Ltd.		
G	16.	WO 97/41255 ✓	11/06/1997	Massachusetts Institute of Technology		
G	17.	EP 00680967 ✓	10/14/1998	Hoechst Marion Roussel		
G	18.	WO 99/51616 ✓	10/14/1999	Pliva, Farmaceutska		
G	19.	EP 0984019 ✓ -	03/08/2000	Pfizer Products Inc.		
G	20.	WO 98/56801	12/17/1998	Pfizer Products Inc.		
G	21.	WO 94/14834 ✓ -	07/07/1994	Rhone-Poulenc Rorer Limited		
G	22.	EP 0984019 A1	03/08/2000	Pfizer Products Inc.		
G	23.	WO 98/56801 ✓ -	12/17/1998	Pfizer Products Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Examiner Signature	G. Pezler	Date Considered	8/5/04
-----------------------	-----------	--------------------	--------




Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				C mplete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/616,046
				Filing Date	July 8, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	5	Attorney Docket Number	03818/100L652-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
g	24. ✓	Gladue R. P. et al., "In Vitro and In Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection," <i>Antimicrob. Agents and Chemother.</i> , 33, 1989, 277-282	
g	25.	Olsen K. M. et al., "Intrapulmonary Pharmacokinetics of Zithromycin in Healthy Volunteers Given Five Oral Doses," <i>Antimicrob. Agents and Chemother.</i> , 40, 1996, 2582-2585	
g	26.	Mikasa, K. et al., "The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice," <i>J. Antimicrob. Chemother.</i> , 30, 1992, 339-348	
g	27.	"Discussion, Genomic organization of axolotl 1g genes," <i>J. Immunol.</i> , 159, 1997, 3395-4005	
g	28.	Takizawa, H. et al., "Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells," <i>Am. J. Respir. Crit. Care Med.</i> , 156, 1997, 266-271	
g	29.	Labro, M.T., "Anti-inflammatory activity of macrolides: a new therapeutic potential?" <i>J. Antimicrob. Chemother.</i> 41, 1998, 37-46	
g	30. *	Cazzola, M., et al., "Potential role of macrolides in the treatment of asthma," <i>Mondaldi Arch. Chest Dis.</i> , 55, 2000, 231-236	
g	31. ✓	Avila, P.C. et al., "Macrolides, asthma, inflammation, and infection," <i>Ann. Allergy Asthma Immunol.</i> , 84, 2000, 565-568	
g	32.	Amayasu, H. et al., "Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma," <i>Ann. Allergy, Asthma & Immunol.</i> , 84, 2000, 594-598	
g	33.	Shoji, T. et al., "Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma," <i>Clin. Exp. Allergy</i> , 29, 999, 950-956	
g	34.	Griffith, E.C., et al., "Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions," <i>Methods in Enzymology</i> , 328m 2000, 89-110	
g	35.	Denis A. et al., "Synthesis and Antibacterial Activity of HMR 36K47, A New Ketolide Highly Potent Against Erythromycin-Resistant and Susceptible Pathogens," <i>Bioorg. & Med. Chem. Lett.</i> , 9, 1999, 3075-3080	
g	36.	Agouridas C. et al., "Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent against Macrolide-Resistant and -Susceptible Respiratory Pathogens," <i>J. Med. Chem.</i> , 41, 1998, 4080-4100	
g	37.	Sun, Or Y. et al. <i>J. Med. Chem.</i> 2000, 43, 1045-1049	
g	38.	McFarland, J. W. et al., "Repromicin Derivatives with Potent Antibacterial Activity against <i>Pasteurella multocida</i> ," <i>J. Med. Chem.</i> , 50, 1997, 1041-1045	
g	39.	Denis A. et al., "Synthesis of 6-O-Methyl-Azithromycin and Its Ketolide Analogue via Beckmann Rearrangement of 9(E)-6-O-Methyl-Erythromycin Oxime," <i>Bioorg. & Med. Chem. Lett.</i> , 8, 1998, 2427-2432	
g	40.	Lartey et al., "Synthesis of 4"-Deoxy Motilides: Identification of a Potent and Orally Active Prokinetic Drug Candidate," <i>J. Med. Chem.</i> , 38, 1998, 1793-1798	

Examiner Signature	<i>g. Rich</i>	Date Considered	3/3/04
-----------------------	----------------	--------------------	--------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/616,046		
		Filing Date	July 8, 2003		
		First Named Inventor	Mladen MERCEP		
		Art Unit	TBA		
		Examiner Name	TBA		
Sheet	3	of	5	Attorney Docket Number	03818/100L652-US1

41.	Kirst, H.A. et al., "34. Metabolism of macrolides," Bryskier, A. J. et al., Ed. <i>Macrolides, Chemistry, Pharmacology and Clinical Use</i> ; Bryskier, Arnette Blackwell: Paris, 1993; pp 485-491
42.	Ma, Z. et al., "Discovery and Development of Ketolides as a New Generation of Macrolide Antimicrobial Agents," <i>Current Medicinal Chemistry - Anti-Infective Agents</i> , 1, 2002, 15-34
43.	Pascual A. et al., "Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells," <i>Clin. Microbiol. Infect.</i> , 7, 2001, 65-69
44.	Hand, W. L. et al., "Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 419-425
45.	Amsden, G. W., "Advanced-generation macrolides: tissue-directed antibiotics," <i>Int. J. Antimicrob. Agents</i> , 18, 2001, 11-15
46.	Johnson, J. D. et al., "Antibiotic uptake by alveolar macrophages," <i>J. Lab. Clin. Med.</i> , 95, 1980, 429-439
47.	Wildfeuer, A. et al., "Uptake of Azithromycin by Various Cells and Its Intracellular Activity under In Vivo Conditions," <i>Antimicrob. Agents Chemother.</i> , 40, 1996, 75-79
48.	Scomeaux, B. et al., "Intracellular Accumulation, Subcellular Distribution, and Efflux of Tilimicosin in Chicken Phagocytes," <i>Poult. Sci.</i> , 77, 1998, 1510-1521
49.	Mtairag, E. M. et al., "Investigation of dirithromycin and erythromycylamine uptake by human neutrophils <i>in vitro</i> ," <i>J. Antimicrob. Chemother.</i> 33, 1994, 523-536
50.	Anderson R. et al., "An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 923-933
51.	Tasaka, Y. et al., "Rokitamycin Uptake by Alveolar Macrophages," <i>Jpn. J. Antibiot.</i> 41, 1988, 836-840
52.	Harf, R. et al., "Spiramycin uptake by alveolar macrophages," <i>J. Antimicrob. Chemother.</i> , 22, 1988, 135-140
53.	Suzuki, T. et al., "General and facile method for determination of configuration of steroid-17-yl-methyl glycolates at C-20 based on kinetic examination," <i>Chem. Soc., Perkin Trans. 1</i> , 1998, 3831-3836
54.	McLean, H.M. et al., "Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9 α -Fluoroprednisolone-16-carboxylate," <i>J. Pharm. Sci.</i> 1994, 83, 476-480
55.	Little, R.J. et al., "Soft Drugs Based on Hydrocortisone: The Inactive Metabolite Approach and Its Application to Steroidal Antiinflammatory Agents," <i>Pharm. Res.</i> , 16, 1999, 961-967
56.	Kertesz, D.J. et al., "Thiol Esters from Steroid 17 β -Carboxylic Acids: Carboxylate Activation and Internal Participation by 17 α -Acylates," <i>J. Org. Chem.</i> , 51, 1986, 2315-2328
57.	Phillipps, G. et al., "Synthesis and Structure - Activity Relationships in a Series of Antiinflammatory Corticosteroid Analogues, Halomethyl Androstane-17 β -carbothioates and 17 β -carboselenoates," <i>J. Med. Chem.</i> 37, 1994, 3717-3729
58.	Bright, G.M. et al., "Synthesis, In Vitro and In Vivo Activity of Novel 9-Deoxy-9a-AZA-9a-Homoerythromycin A Derivatives; A new Class of Macrolide Antibiotics, the Azalides" <i>J. Antibiot.</i> , 41, 1998, 1029-1047
59.	Costa, A.M. et al., "Hybrids of macrolides and nucleobases or nucleosides," <i>Tetrahedron Letters</i> , 41, 2000, 3371-3375

Examiner Signature	<i>A. Peller</i>	Date Considered	8/5/03
--------------------	------------------	-----------------	--------



PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				C mplete if Kn wn	
				Application Number	10/616,046
				Filing Date	July 8, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	4	of	5	Attorney Docket Number	03818/100L652-US1

60.	Newman, S.P. et al., "Evaluation of jet nebulisers for use with gentamicin solution," <i>Thorax</i> , 40, 1985, 671-676
61.	Berenberg, M.J. et al., "Comparison of Metered-Dose Inhaler Attached to an Aerochamber with an Updraft Nebulizer for the Administration of Metaproterenol in Hospitalized Patients," <i>J. Asthma USA</i> , 22, 1985, 87-92
62.	Wamer, Timothy D. et al., "Nonsteroid drug selectivities for cyclo-oxygenase -1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis," <i>Proc. Natl. Acad. Sci. USA</i> 96, June 1999, 7563-7568
63.	Luong, Brigitte T. et al., "Treatment Options for Rheumatoid Arthritis: Celecoxib, Leflunomide, Etanercept, and Infliximab," <i>The Annals of Pharmacotherapy</i> 34, 2000, 743-760
64.	Taketo, Makoto M., "Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)," <i>Journal of the National Cancer Institute</i> 90, 21, 1998, 1609-1620
65.	Fournier, David B. et al., "COX-2 and Colon Cancer: Potential Targets for Chemoprevention," <i>Journal of Cellular Biochemistry Supplement</i> 34, 2000, 34-97
66.	Carswell, E.A. et al., "An endotoxin-induced serum factor that causes necrosis of tumors," <i>Proc. Nat. Acad. Sci. USA</i> 72, 9, 1975, 3666-3670
67.	Elliott, Michael J. et al., "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>The Lancet</i> 344, 1994, 1005-1110
68.	Mori, Lucia et al., "Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)-IgG1-Treated and TNFR1-Deficient Mice," <i>Journal of Immunology</i> , 1996, 3178-3182
69.	Pfeffer, Klaus et al., "Mice Deficient for the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection," <i>Cell</i> 73, 1993, 457-467
70.	Georgopoulos, Spiros et al., "Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis in Transgenic Mice," <i>Journal of Inflammation</i> 46, 1996, 86-97
71.	Keffer, Jeanne et al., "Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis," <i>The EMBO Journal</i> 10, 13, 1991, 4025-4031
72.	Van Assche, Gert et al., "Anti-TNF agents in Crohn's disease," <i>Exp. Opin. Invest. Drugs</i> , 2000, 103-111
73.	Romo, Daniel et al., "Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of a β -Lactam-Based Macrocyclization," <i>J. Am Chem. Soc.</i> 120, 1998, 12237-12254
74.	Huang, Chun-Ming et al., "Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis," <i>Chemistry & Biology</i> 7, 9, 2000, 453-461
75.	Pandor, Mark W. et al., "Photochemical Control of the Infectivity of Adenoviral Vectors Using a Novel Photocleavable Biotinylation Reagent," <i>Chemistry & Biology</i> 9, 2002, 567-573
76.	Colliet, H.O.J. et al., "The Abdominal Constriction Response and Its Suppression by Analgesic Drugs in the Mous," <i>Br. J. Pharmac. Thermother.</i> 32, 1968, 295-310
77.	Fukawa, Kazunaga et al., "A Method for Evaluating Analgesic Agents in Rats," <i>Journal of Pharmacological Methods</i> 4, 1980, 251-259

Examiner Signature	<i>G. P. ...</i>	Date Considered	8/15/04
--------------------	------------------	-----------------	---------



PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/616,046
				Filing Date	July 8, 2003
				First Named Inventor	Mladen MERCEP
				Art Unit	TBA
				Examiner Name	TBA
Sheet	5	of	5	Attorney Docket Number	03818/100L652-US1

78.	Schweizer, A. et al., "Combined automated writhing/motility test for testing analgesics," <i>Agents and Actions</i> 23, 1/2, 1988, 29-31	
-----	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

M:\3818\100L650US1\00044185.DOC

Examiner Signature	G. Peck	Date Considered	8/6/03
-----------------------	---------	--------------------	--------